COST EFFECTIVENESS OF EMPAGLIFLOZIN IN PATIENTS WITH T2DM AND HIGH CV RISK IN CANADA

Author(s)

Mettam SR¹, Bajaj H², Kansal AR³, Kandaswamy P⁴
¹Boehringer Ingelheim, Burlington, ON, Canada, ²LMC Diabetes & Endocrinology, Brampton, ON, Canada, ³Evidera, Bethesda, MD, USA, ⁴Boehringer Ingelheim GmbH, Ingelheim, Germany

Presentation Documents

PDB52--strong-u-mettam-sr-u-sup-1-sup-strong-bajaj-h-sup-2-sup-kansal-ar-sup-3-sup-kandaswamy-p-sup-4-sup-br-sup-1-sup-boehringer-ingelheim-burlington-on-canada-sup-2-sup-lmc-diabetes-endocrinology-brampton-on-canada-sup-3-sup-evidera-bethe ...

Conference/Value in Health Info

2016-10, ISPOR Europe 2016, Vienna, Austria

Value in Health, Vol. 19, No. 7 (November 2016)

Code

PDB52

Topic

Economic Evaluation

Topic Subcategory

Cost-comparison, Effectiveness, Utility, Benefit Analysis

Disease

Cardiovascular Disorders, Diabetes/Endocrine/Metabolic Disorders

Explore Related HEOR by Topic

Economic Evaluation

Presentation